PMID: 24318956
Question: Is digoxin use for cardiovascular disease associated with risk of prostate cancer?
Correct Answer: yes

======================= Launch the MCC process =======================
PMID: 24318956
Question: Is digoxin use for cardiovascular disease associated with risk of prostate cancer?
Correct Answer: yes

======================= Launch the MCC process =======================
PMID: 24318956
Question: Is digoxin use for cardiovascular disease associated with risk of prostate cancer?

----- GPT's initial response -----
GPT is reasoning the answer...


**1. Question Analysis**
- **Core Content**: The question seeks to determine whether the use of digoxin for cardiovascular disease is associated with the risk of developing prostate cancer (PCa).
- **Key Information to Identify**:
  - Relationship between digoxin use and PCa risk.
  - Study design and population.
  - Statistical significance and strength of association.
  - Limitations and potential confounders.

**2. Evidence Evaluation**
- **Research Results and Data**:
  - The study analyzed 1,001 PCa cases and 942 controls.
  - Digoxin use was present in 2.7% of controls.
  - Overall, digoxin use was associated with a reduced odds ratio (OR) for PCa (OR 0.58, 95% CI: 0.30-1.10), though this was not statistically significant since the confidence interval includes 1.
  - In a subgroup with ≥3 PSA tests over the preceding 5 years, the association was stronger and statistically significant (OR 0.44, 95% CI: 0.20-0.98).
- **Strength and Reliability**:
  - Population-based case-control design is appropriate for assessing associations.
  - The sample size is moderate, but the low prevalence of digoxin use (2.7%) may limit statistical power.
- **Relevance**:
  - The study directly addresses the relationship between digoxin use and PCa risk.
- **Limitations**:
  - The overall association was not statistically significant.
  - Potential confounding factors may not be fully accounted for.
  - The low prevalence of digoxin use could affect the robustness of the findings.
  - The study calls for further research, indicating that findings are preliminary.
- **Contradictory Evidence**:
  - The primary analysis did not reach statistical significance.
  - Only a specific subgroup showed a significant association, which may not be generalizable.
- **Alternative Explanations**:
  - The observed association in the subgroup could be due to confounding factors related to PSA screening frequency.

**3. Conclusion**
While the study suggests a potential association between digoxin use and reduced PCa risk, the overall findings were not statistically significant, and the significant result was limited to a specific subgroup. The low prevalence of digoxin use and the call for further research indicate that the evidence is not yet conclusive. Therefore, the current evidence is suggestive but not definitive.

**4. Final Answer:**
**My final choice is: "maybe"**
GPT selected: maybe

----- Qwen's initial response -----
Qwen is reasoning the answer...


**1. Question Analysis**  
The question asks whether digoxin use for cardiovascular disease is associated with a reduced risk of prostate cancer (PCa). Key elements to assess include the study design, statistical associations (odds ratios and confidence intervals), confounder adjustment, and subgroup analyses.  

**2. Evidence Evaluation**  
- **Main Analysis**: The multivariate analysis found an OR of 0.58 (95% CI: 0.30–1.10) for digoxin use and PCa risk. This suggests a potential reduction in risk, but the confidence interval includes 1, indicating statistical nonsignificance.  
- **Subgroup Analysis**: Among individuals with frequent PSA screening (≥3 tests in 5 years), the OR dropped to 0.44 (95% CI: 0.20–0.98), which is statistically significant (CI excludes 1). However, this subgroup may be biased, as PSA screening frequency could influence PCa detection rather than actual risk.  
- **Study Limitations**:  
  - **Case-control design**: Prone to recall bias (e.g., participants retrospectively reporting digoxin use).  
  - **Small exposed group**: Only 2.7% of controls used digoxin, leading to limited statistical power.  
  - **Confounding**: While adjusted for PSA screening, race, and family history, residual confounding (e.g., other lifestyle factors) remains possible.  
- **Mixed Evidence**: The abstract acknowledges that while preclinical studies support anti-tumor effects, the human data here are inconclusive due to nonsignificant main results and subgroup limitations.  

**3. Conclusion**  
The study provides **mixed evidence**. The primary analysis shows a nonsignificant trend toward reduced PCa risk with digoxin, while a subgroup analysis suggests a stronger association. However, the nonsignificant main result, small sample size of digoxin users, and potential biases (e.g., PSA screening influencing detection) weaken the certainty. The abstract itself states "may be associated," emphasizing the need for further research. Thus, the evidence is insufficient to confirm an association definitively.  

**4. Final Answer**:  
**My final choice is: "maybe"**
Qwen selected: maybe

----- Deepseek's initial response -----
DeepSeek is reasoning the answer...

**1. Question Analysis**  
The question asks whether digoxin use for cardiovascular disease is associated with prostate cancer (PCa) risk. The abstract evaluates this association using a case-control study, focusing on adjusted odds ratios (ORs) and subgroup analyses. Key information includes the reported ORs, confidence intervals (CIs), and adjustments for confounders like age, PSA screening, and family history.

**2. Evidence Evaluation**  
- **Primary Analysis**: The multivariate-adjusted OR for PCa risk with digoxin use was **0.58 (95% CI: 0.30–1.10)**, indicating a non-significant trend toward reduced risk (CI includes 1.0).  
- **Subgroup Analysis**: In individuals with ≥3 PSA tests, digoxin use showed a statistically significant reduction in PCa risk (**OR 0.44, 95% CI: 0.20–0.98**).  
- **Strengths**: The study adjusted for major confounders and noted preclinical plausibility for digoxin’s anti-tumor effects.  
- **Limitations**:  
  - Observational design prevents causal inference.  
  - Low prevalence of digoxin use (2.7% in controls) reduces statistical power.  
  - Subgroup findings (e.g., PSA-screened individuals) may reflect detection bias or residual confounding.  
  - The primary analysis lacked statistical significance, and subgroup results require cautious interpretation.  

**3. Conclusion**  
The evidence suggests a *potential* association between digoxin use and reduced PCa risk, particularly in a subgroup with frequent PSA testing. However, the primary analysis was inconclusive (CI spanning 1.0), and limitations inherent to observational studies (e.g., confounding, selection bias) preclude definitive conclusions. The authors explicitly call for further research, underscoring the preliminary nature of these findings.  

**4. Final Answer**  
**My final choice is: maybe**
DeepSeek selected: maybe

Initial consensus: All models selected maybe